Patents by Inventor Christiane Kofink

Christiane Kofink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
    Patent number: 11814380
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: November 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Christiane Kofink, Heinz Stadtmueller, Tobias Wunberg, Marco Hans Hofmann, Anke Baum, Michael Gmachl, Dorothea Ingrid Rudolph, Fabio Savarese, Markus Ostermeier, Markus Frank, Annika Gille, Stefan Goepper, Marco Santagostino, Julian Wippich
  • NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS
    Publication number: 20210177851
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: October 22, 2020
    Publication date: June 17, 2021
    Inventors: Michael GMACHL, Michael SANDERSON, Dirk KESSLER, Christiane KOFINK, Matthew Russell NETHERTON, Juergen RAMHARTER, Tobias WUNBERG, Marco HOFMANN, Fabio SAVARESE, Anke BAUM, Dorothea RUDOLPH
  • Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
    Patent number: 10898487
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 26, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Kessler, Christiane Kofink, Matthew Russell Netherton, Juergen Ramharter, Tobias Wunberg
  • NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS
    Publication number: 20210009588
    Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Inventors: Juergen RAMHARTER, Christiane KOFINK, Heinz STADTMUELLER, Tobias WUNBERG, Marco Hans HOFMANN, Anke BAUM, Michael GMACHL, Dorothea Ingrid RUDOLPH, Fabio SAVARESE, Markus OSTERMEIER, Markus FRANK, Annika GILLE, Stefan GOEPPER, Marco SANTAGOSTINO, Julian WIPPICH
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10882866
    Abstract: The present invention encompasses intermediates for preparing compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: January 5, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
    Patent number: 10829487
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 10, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Ramharter, Christiane Kofink, Heinz Stadtmueller, Tobias Wunberg
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10717742
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Annika Gille, Stefan Goepper, Manuel Henry, Guenther Huchler
  • NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS
    Publication number: 20190358230
    Abstract: The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 28, 2019
    Inventors: Michael GMACHL, Michael SANDERSON, Dirk KESSLER, Christiane KOFINK, Matthew Russell NETHERTON, Juergen RAMHARTER, Tobias WUNBERG, Marco HOFMANN, Fabio SAVARESE, Anke BAUM, Dorothea RUDOLPH
  • NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS
    Publication number: 20190194192
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Juergen RAMHARTER, Christiane KOFINK, Heinz STADTMUELLER, Tobias WUNBERG, Marco Hans HOFMANN, Anke BAUM, Michael GMACHL, Dorothea Ingrid RUDOLPH, Fabio SAVARESE, Markus OSTERMEIER, Markus FRANK, Annika GILLE, Stefan GOEPPER, Marco SANTAGOSTINO, Julian WIPPICH
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10144739
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Joachim Broeker, Nina Kerres, Christiane Kofink, Juergen Ramharter, Harald Weinstabl
  • Spiro[3H-indole-3,2?-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
    Patent number: 10138251
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Gollner, Christiane Kofink, Juergen Ramharter, Harald Weinstabl, Tobias Wunberg
  • NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS
    Publication number: 20180291030
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Andreas GOLLNER, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Tobias WUNBERG
  • NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS
    Publication number: 20180273541
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: June 8, 2018
    Publication date: September 27, 2018
    Inventors: Andreas GOLLNER, Joachim BROEKER, Nina KERRES, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Annika GILLE, Stefan GOEPPER, Manuel HENRY, Guenther HUCHLER
  • NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS
    Publication number: 20170174695
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, R7, A, D, E, F, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
    Type: Application
    Filed: October 7, 2016
    Publication date: June 22, 2017
    Inventors: Andreas GOLLNER, Joachim BROEKER, Nina KERRES, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Annika GILLE, Stefan GOEPPER, Manuel HENRY, Guenther HUCHLER
  • NEW SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS
    Publication number: 20150291611
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, V, W, X, Y, n and q are defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases and synthetic intermediates.
    Type: Application
    Filed: April 10, 2015
    Publication date: October 15, 2015
    Inventors: Andreas GOLLNER, Christiane KOFINK, Juergen RAMHARTER, Harald WEINSTABL, Tobias WUNBERG
  • 1-imidazo[4,5-]quinolines
    Patent number: 8895581
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R7, Qa, Qb, L, n and m are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations containing such compounds and their use as medicaments.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: November 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Harald Engelhardt, Christiane Kofink
  • Pyridons as PDK1 inhibitors
    Patent number: 8637549
    Abstract: The present invention encompasses compounds of general formula (1) while the groups R4 to R7 and the units W, L, Qa and QH are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: January 28, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Guido Boehmelt, Christiane Kofink, Daniel Kuhn, Darryl McConnell, Heinz Stadtmueller
  • Chemical compounds
    Patent number: 8575203
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: November 5, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Christiane Kofink, Darryl McConnell
  • 1H-IMIDAZO[4,5-C]QUINOLINES
    Publication number: 20130210832
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R7, Qa, Qb, L, n and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations containing such compounds and their use as medicaments.
    Type: Application
    Filed: May 17, 2011
    Publication date: August 15, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Darryl McConnell, Harald Engelhardt, Christiane Kofink
  • NEW CHEMICAL COMPOUNDS
    Publication number: 20120094976
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
    Type: Application
    Filed: April 19, 2011
    Publication date: April 19, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Harald Engelhardt, Christiane Kofink, Darryl McConnell